NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 15:59இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
BHAGCHEM Q2 Revenue Up 21% YoY to ₹169.9 Cr, PAT Flat at ₹5.4 Cr on Higher Finance Costs
Bhagiradha Chemicals released its Q2 & H1 FY27 investor presentation. For Q2 FY27, consolidated revenue from operations grew 21.3% YoY to ₹169.9 Cr, while EBITDA increased 50.9% YoY to ₹22.7 Cr. However, Q2 PAT fell 1.8% YoY to ₹5.4 Cr, weighed down by higher depreciation (₹9.0 Cr vs ₹4.0 Cr) and interest expenses (₹7.6 Cr vs ₹4.1 Cr) following capex ramp-up at Bheema Fine Chemicals. For H1 FY27, revenue reached ₹364.9 Cr (+38% YoY) and PAT nearly doubled to ₹18.7 Cr (+98% YoY).
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company published its detailed Q2 & H1 FY27 investor presentation following quarterly results, detailing operational performance across subsidiaries.
ஏன் இது முக்கியம்While volume growth from the Bheema facility is driving topline expansion, heavy depreciation and debt-service costs are capping quarterly net profit conversion.
Q2 FY27 Revenue: ₹169.9 கோடிQ2 FY27 EBITDA: ₹22.7 கோடிQ2 FY27 PAT: ₹5.4 கோடிH1 FY27 Working Capital Outflow: -₹142.1 கோடிCumulative Bheema Capex (2.5 yrs): ~Rs 514 CrsBheema Capex vs Net Worth: ~69.7%
📅 குறுகிய காலம்Muted net profit growth (-59% QoQ, flat YoY) and severe working capital drag on cash flow may keep near-term sentiment cautious.
📈 நீண்ட காலம்Long-term trajectory depends on sustained capacity ramp-up of the 9,002 MT Bheema facility, new molecule introductions, and operating leverage to offset increased fixed costs.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow of -₹93.4 Cr in H1 FY27 due to sharp inventory and debtor buildup
Elevated leverage with total borrowings rising to ~₹367.8 Cr (D/E up to 0.5x)
Weather disruptions and rainfall deficits impacting domestic agrochemical demand
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and margin stabilization at the Bheema Fine Chemicals plant, along with working capital normalization as debt-to-equity increased to 0.5x in H1 FY27.
Q2 FY27 Standalone PAT Falls 31% YoY to ₹4.08 Cr Despite 9.1% Revenue Growth
Bhagiradha Chemicals reported standalone revenue from operations of ₹146.64 Cr for Q2 ended September 30, 2026, rising 9.1% YoY from ₹134.36 Cr in Q2 FY26, but falling 15.6% sequentially from ₹173.67 Cr. Standalone net profit declined 31.1% YoY to ₹4.08 Cr (vs ₹5.92 Cr in Q2 FY26) and 61.8% QoQ, pressured by higher input costs. For H1 FY27, revenue reached ₹320.31 Cr compared to ₹258.14 Cr in H1 FY26, while H1 net profit was marginally higher at ₹14.76 Cr versus ₹14.20 Cr. Operating cash flow for H1 FY27 turned negative to -₹12.25 Cr due to working capital expansion, primarily driven by inventory build-up.
உச்சம் நம்பிக்கை
என்ன மாறியதுBhagiradha Chemicals declared its un-audited standalone and consolidated Q2 and H1 FY27 financial results showing sequential and YoY profitability compression.
ஏன் இது முக்கியம்Operating margins shrank sharply in Q2 amid elevated material costs and industry oversupply, turning operating cash flow negative for the first half of the year.
Revenue from Operations (Q2): ₹14,663.87 லட்சம்Net Profit (Q2): ₹407.78 லட்சம்Cost of Materials Consumed (Q2): ₹13,021.42 லட்சம்Operating Cash Flow (H1): -₹1,224.81 lakhsShort-term Borrowings (Sep 2026): ₹10,344.53 லட்சம்
📅 குறுகிய காலம்Margin pressure and sequential drop in profitability may weigh on stock sentiment in the near term.
📈 நீண்ட காலம்Performance will hinge on margin recovery in technical agrochemicals, stabilization of Chinese supply dynamics, and backward integration benefits from Bheema Fine Chemicals.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility with material costs outpacing revenue growth
Negative operating cash flow driven by working capital lock-in (₹64 Cr inventory surge in H1)
Increase in short-term debt to ₹103.45 Cr from ₹66.21 Cr in March 2026
👀 கவனிக்க வேண்டியவை
Track whether high raw material inventory liquidates profitably in H2 and monitor the ramp-up of the Bheema Fine Chemicals expansion facility.
Ind-Ra Assigns 'IND BBB+/Stable' to Bhagiradha Chem's Arm for ₹600 Cr Facilities
India Ratings and Research (Ind-Ra) has assigned 'IND BBB+/Stable/IND A2+' to the ₹600 Cr (INR 6,000 million) bank loan facilities of Bheema Fine Chemicals Private Limited, a wholly owned subsidiary of Bhagiradha Chemicals. The rating is backed by an unconditional and irrevocable corporate guarantee from the parent. Ind-Ra highlighted the ongoing ₹950 Cr total capex outlay to add 9,000 MTPA capacity, of which ₹600 Cr was incurred by June 2026. The expansion will lift aggregate capacity from 3,250 MTPA to 12,250 MTPA, with the subsidiary expected to contribute ~70% of consolidated business upon full ramp-up.
உச்சம் நம்பிக்கை
என்ன மாறியதுCredit rating agency Ind-Ra assigned an investment-grade rating of IND BBB+/Stable for ₹600 Cr bank facilities of subsidiary Bheema Fine Chemicals.
ஏன் இது முக்கியம்Secures banking lines and formalizes credit evaluation for Bhagiradha's massive ₹950 Cr expansion project (larger than its FY26 revenue of ₹536 Cr), which nearly quadruples group manufacturing capacity.
📅 குறுகிய காலம்Reaffirms banking and funding stability for the subsidiary's ongoing capex without near-term refinancing pressures.
📈 நீண்ட காலம்The 9,000 MTPA expansion significantly improves backward integration, reduces raw material dependency on China, and could structurally scale consolidated revenues by FY28.
⚠ அபாய எச்சரிக்கைகள்
Elevated consolidated net leverage (4.3x net debt/EBITDA in FY26) due to debt-funded capex.
Execution and stabilization risks for Phase 2 capacity expansion.
High working capital intensity and agrochemical regulatory risks.
👀 கவனிக்க வேண்டியவை
Track the commissioning and utilization ramp-up of Phase 2 capacity across FY27-FY28 and monitor debt reduction as operating cash flows normalize.
58% Revenue Growth in Q1 FY27; EBITDA Jumps 240% on Bheema Plant Ramp-up
Bhagiradha Chemicals reported a strong Q1 FY27 with consolidated revenue reaching ₹195.0 Cr, a 58% YoY increase. EBITDA surged 240% YoY to ₹30.5 Cr, with margins expanding significantly to 15.7% from 7.3% in the year-ago period. This performance was driven by the ramp-up of the Bheema Fine Chemicals facility, where capacity utilization nearly doubled compared to Q4 FY26. The company also introduced four new mid-to-high value molecules, contributing to a richer product mix and improved realizations.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a heavy capex phase (₹450 Cr invested in Bheema) to an operational ramp-up phase, resulting in its highest-ever quarterly performance.
ஏன் இது முக்கியம்The new Bheema facility nearly triples the company's total capacity (9,002 MT vs 3,250 MT standalone) and focuses on higher-margin products, structurally improving the company's profitability profile.
📅 குறுகிய காலம்The stock may react positively to the sharp recovery in margins and the 'highest-ever' quarterly revenue and profit figures.
📈 நீண்ட காலம்Structural growth is expected as the Bheema facility scales up and the company reduces its reliance on low-margin products at its older facility.
⚠ அபாய எச்சரிக்கைகள்
High dependency on China for 20-25% of raw materials
👀 கவனிக்க வேண்டியவை
Watch for the continued utilization ramp-up at the Bheema facility and the successful commercialization of the remaining 6 out of 10 new products under development to sustain margin expansion.
Bhagiradha Chemicals reported a robust start to FY27 with consolidated revenue growing 57.5% YoY to ₹195.02 Cr. Net profit surged 235% YoY to ₹13.33 Cr, compared to ₹3.98 Cr in the same quarter last year. The performance indicates strong operating leverage as the Bheema Fine Chemicals subsidiary scales up, with Q1 revenue alone representing 36.4% of the previous TTM revenue. Despite higher finance costs of ₹6.43 Cr, consolidated PBT rose 601% YoY, reflecting improved product realizations and capacity utilization.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has reported a significant turnaround in profitability and revenue growth, moving from a TTM PAT of ₹18 Cr to a single-quarter PAT of ₹13.33 Cr.
ஏன் இது முக்கியம்This result validates the company's ₹800+ Cr expansion strategy at its Bheema subsidiary, showing that the new capacity is contributing meaningfully to both top-line growth and bottom-line margins despite global industry headwinds.
Consolidated Revenue (Q1): ₹195.02 கோடிConsolidated Net Profit (Q1): ₹13.33 கோடிQ1 வருவாய் vs TTM வருவாய்: 36.4%Q1 Profit vs TTM Profit: 74.0%Finance Costs (Q1): ₹6.43 கோடி
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the massive earnings beat and significant margin expansion compared to the previous four quarters.
📈 நீண்ட காலம்Structurally positive as the company scales its 9,002 MT capacity at Bheema; however, the high P/E ratio of 214.8 requires sustained high growth to justify current valuations.
⚠ அபாய எச்சரிக்கைகள்
High finance costs (₹6.43 Cr per quarter)
Low promoter holding (19.6%)
Regulatory risk regarding Chlorpyriphos ban
Raw material dependency on China (20-25%)
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 15.6% estimated EBITDA margin and the ramp-up progress of the Bheema Fine Chemicals facility. Key risks to watch include the potential regulatory ban on Chlorpyriphos and the impact of high finance costs on net margins.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
BHAGCHEM Q1 FY27: Consolidated Revenue up 57% YoY to ₹195 Cr; PBT jumps 7x to ₹17.5 Cr
Bhagiradha Chemicals reported a strong start to FY27 with consolidated revenue reaching ₹195.02 Cr, a 57.5% increase over Q1 FY26. Profitability showed a sharp recovery, with Consolidated Profit Before Tax (PBT) rising to ₹17.54 Cr from just ₹2.50 Cr in the year-ago period. This growth is largely driven by the ramp-up of the Bheema Fine Chemicals subsidiary, which added 9,002 MT of capacity. However, finance costs have doubled to ₹6.43 Cr YoY, reflecting the capital-intensive nature of recent expansions.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has achieved a significant jump in quarterly revenue run-rate (₹195 Cr vs TTM average of ₹134 Cr) following its capacity expansion.
ஏன் இது முக்கியம்The results validate the ₹800+ Cr investment in the Bheema subsidiary, showing that the new capacity is translating into both top-line growth and improved operational leverage.
Consolidated Revenue (Q1): ₹195.02 கோடிYoY Revenue Growth: 57.5%Q1 வருவாய் vs TTM வருவாய்: 36.4%Consolidated PBT: ₹17.54 கோடிFinance Costs: ₹6.43 கோடி
📅 குறுகிய காலம்The stock may react positively to the sharp jump in consolidated profitability and revenue growth that exceeds historical quarterly averages.
📈 நீண்ட காலம்Structural growth depends on the successful integration of the Bheema facility and the development of 10 new products to diversify the portfolio.
⚠ அபாய எச்சரிக்கைகள்
High finance costs relative to quarterly PAT
Chinese oversupply impacting global pricing power
High valuation with a P/E exceeding 200
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of operating margins as the Bheema facility scales up and watch for any impact from global agrochemical pricing volatility due to Chinese oversupply.
Bhagiradha Chemicals FY26 PAT Grows 31% to ₹18.2 Cr; EBITDA Surges 55% on Capacity Expansion
Bhagiradha Chemicals reported a strong financial performance for FY26, with consolidated revenue rising 22% to ₹535.9 crore and EBITDA increasing 55% to ₹57.1 crore. The growth was driven by a combination of volume expansion and improved value realizations, alongside the successful commencement of Phase I of the Bheema Fine project (₹400 crore capitalization). While PAT grew 31% to ₹18.2 crore, the bottom line was partially moderated by higher depreciation and finance costs associated with the new facility. Management has set an ambitious long-term target to scale revenue by 3.5x over the next 4-5 years.
முக்கிய அம்சங்கள்
FY26 Revenue grew 22% YoY to ₹535.9 crore, while EBITDA margins expanded from 8.4% to 10.7%.Q4FY26 EBITDA surged 220% YoY to ₹19.4 crore, reflecting strong operating leverage and improved capacity utilization.Successfully commissioned Phase I of Bheema Fine Chemicals with an incremental capacity potential of 9,002 MTPA.Launched 3 new molecules and added 19 new customers, including 5 major accounts, during the fiscal year.Board recommended a final dividend of ₹0.15 (15%) per equity share of face value ₹1.
👀 கவனிக்க வேண்டியவை
Investors should focus on the utilization ramp-up of the Bheema Fine facility in FY27, which is expected to be a primary growth driver. The company's aggressive 4-5 year revenue target and focus on backward integration make it a strong candidate for long-term monitoring in the agrochemical space.
Bhagiradha Chemicals reported a strong 19.4% year-on-year growth in annual revenue, reaching ₹521.22 crore for FY26. While full-year profit after tax saw a marginal decline to ₹26.24 crore from ₹27.39 crore, the Q4 performance was robust with net profit rising 39.6% YoY to ₹7.21 crore. The Board has recommended a final dividend of ₹0.15 per share (15% of face value). Additionally, the company has transitioned to a lower corporate tax rate of 22% effective April 1, 2025.
முக்கிய அம்சங்கள்
Annual Revenue from Operations grew 19.4% YoY to ₹52,122.21 lakhs in FY26.Q4 FY26 Profit After Tax increased by 39.6% YoY to ₹720.61 lakhs compared to ₹516.20 lakhs in Q4 FY25.Recommended a final dividend of ₹0.15 per equity share (15%) for the financial year ended March 31, 2026.Total Assets increased to ₹94,810.20 lakhs as of March 31, 2026, from ₹91,384.03 lakhs in the previous year.Company opted for a concessional corporate tax rate of 22% starting FY26, resulting in a deferred tax liability reduction of ₹307.75 lakhs.
👀 கவனிக்க வேண்டியவை
The strong Q4 recovery and healthy revenue growth indicate positive momentum in the crop protection segment. Investors should monitor if the transition to a lower tax regime and improved Q4 margins lead to sustained profit growth in FY27.
Bhagiradha Chemicals Recommends ₹0.15 Final Dividend for FY 2025-26
The Board of Directors of Bhagiradha Chemicals & Industries Limited has recommended a final dividend of ₹0.15 per equity share for the financial year ended March 31, 2026. This dividend represents a 15% payout on the face value of ₹1 per share. The proposal is subject to shareholder approval at the 33rd Annual General Meeting scheduled for July 31, 2026. The company has established July 23, 2026, as the record date for determining eligible shareholders.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹0.15 per equity share of face value ₹1 eachDividend payout ratio stands at 15% of the face valueRecord date for dividend eligibility is set for Thursday, July 23, 2026Book closure period scheduled from July 24, 2026, to July 31, 2026Final approval to be sought at the 33rd AGM on July 31, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the record date of July 23, 2026. While the absolute dividend amount is small, it reflects the company's commitment to returning capital to shareholders.
Bhagiradha Chemicals Q4 Net Profit Jumps 39% to ₹7.21 Cr; Declares ₹0.15 Dividend
Bhagiradha Chemicals reported a strong Q4 FY26 with revenue from operations growing 21.6% YoY to ₹149.16 crore. Net profit for the quarter rose significantly by 39.6% YoY to ₹7.21 crore, up from ₹5.16 crore in the previous year. For the full fiscal year 2026, revenue increased by 19.4% to ₹521.22 crore, although annual net profit saw a slight dip of 4.2% to ₹26.24 crore. The Board has recommended a final dividend of ₹0.15 per share (15%) for the financial year.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue from operations rose 21.6% YoY to ₹14,916.17 Lakhs.Q4 FY26 Net Profit increased 39.6% YoY to ₹720.61 Lakhs from ₹516.20 Lakhs.Full-year FY26 Revenue reached ₹52,122.21 Lakhs compared to ₹43,635.74 Lakhs in FY25.Recommended a final dividend of ₹0.15 per equity share of face value ₹1.Finance costs for the full year increased to ₹1,138.76 Lakhs from ₹664.12 Lakhs in the previous year.
👀 கவனிக்க வேண்டியவை
The strong Q4 recovery suggests improving operational efficiency; investors should monitor if this momentum continues into FY27. The stock remains a watch for those interested in the crop protection chemicals sector given the steady revenue growth.
Bhagiradha Chemicals Credit Rating Affirmed at IND BBB+; Outlook Revised to Stable
India Ratings and Research (Ind-Ra) has affirmed the credit ratings for Bhagiradha Chemicals & Industries Limited's bank loan facilities totaling INR 1,730 million. While the long-term rating remains at 'IND BBB+' and the short-term rating at 'IND A2+', the outlook has been revised from 'Positive' to 'Stable'. This revision suggests a moderation in the expectations for immediate credit profile improvement compared to the previous assessment. The rated facilities include working capital limits and term loans from major lenders including SBI, Axis Bank, RBL, and ICICI Bank.
முக்கிய அம்சங்கள்
India Ratings affirmed the long-term rating at 'IND BBB+' and short-term rating at 'IND A2+'The outlook for the company's bank facilities was revised from 'Positive' to 'Stable'Total bank loan facilities rated amount to INR 1,730 million (INR 173 Crores)The facilities include a specific term loan of INR 328.40 million from Axis BankLenders involved include State Bank of India, Axis Bank, RBL Bank, and ICICI Bank
👀 கவனிக்க வேண்டியவை
Investors should note the revision in outlook to 'Stable', which indicates a steady credit profile but slower improvement than previously anticipated. Monitor the company's debt-to-equity and interest coverage ratios in upcoming quarterly results.
Bhagiradha Chemicals reported a steady Q3FY26 with revenue growing 11% YoY to ₹114 Cr, driven by improved price realizations despite a seasonal volume dip. EBITDA saw a significant 49% YoY increase to ₹13.7 Cr as gross margins expanded by 311 bps to 43% due to a favorable product mix and process improvements. However, 9MFY26 PAT declined slightly by 4% YoY to ₹14.1 Cr, primarily due to higher finance costs from working capital utilization and increased depreciation. The company is aggressively pursuing an ₹800 Cr expansion plan, with Phase 1 of the Bheema facility now ready for a production ramp-up.
முக்கிய அம்சங்கள்
Q3FY26 EBITDA grew 49% YoY to ₹13.7 Cr with margins expanding to 12.0% from 8.9% YoY.Gross margins reached 43.0% in Q3FY26, a 311 bps YoY improvement led by process upgrades and better product mix.9MFY26 revenue rose 19% YoY to ₹377.8 Cr, supported by double-digit growth in average price realizations.Total capex plan of ₹800 Cr is underway, including a ₹70 Cr solar project and ₹350 Cr allocated for Phase 2.Phase 1 of the Bheema facility is geared for a structured ramp-up of 5 to 8 molecules over the next 3 months.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful ramp-up of the Bheema facility which is key to achieving the company's long-term revenue targets. While high interest costs are currently weighing on PAT, the significant expansion in gross margins indicates strong operational efficiency and pricing power.
Bhagiradha Chemicals Appoints Ranjit Kumar Kilaru as New CFO Effective March 1, 2026
Bhagiradha Chemicals & Industries has announced a leadership transition in its finance department. Mr. B. Krishna Mohan Rao will retire as the Chief Financial Officer on February 28, 2026. He will be succeeded by Mr. Ranjit Kumar Kilaru, who takes over the role on March 1, 2026. Mr. Kilaru is a Chartered Accountant with over 23 years of experience in banking and manufacturing, including a 13-year tenure at Axis Bank.
முக்கிய அம்சங்கள்
Retirement of Mr. B. Krishna Mohan Rao as CFO effective February 28, 2026.Appointment of Mr. Ranjit Kumar Kilaru as the new CFO starting March 1, 2026.Incoming CFO brings 23+ years of experience across banking, manufacturing, and financial advisory.Mr. Kilaru previously served as Deputy Vice President and Centre Head – SME at Axis Bank for 13 years.The transition includes updating the list of Key Managerial Personnel authorized for materiality determinations.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine management transition; however, the new CFO's extensive banking and debt syndication background may benefit the company's future capital structuring. No immediate action is required other than monitoring for any shifts in financial reporting or strategy.
BHAGCHEM Q3 Net Profit Drops 32.3% YoY to ₹4.83 Cr; Appoints New CFO
Bhagiradha Chemicals reported a 10.9% YoY increase in revenue to ₹113.92 crore for Q3 FY26, yet net profit declined significantly by 32.3% to ₹4.83 crore. On a sequential basis, performance was weaker with revenue and profit falling 15.2% and 18.4% respectively compared to Q2 FY26. The company is undergoing a leadership transition as CFO Mr. B. Krishna Mohan Rao retires, to be succeeded by Mr. Ranjit Kumar Kilaru, a CA with 23 years of experience, effective March 1, 2026. Despite 18.6% revenue growth in the nine-month period, overall profitability remains under pressure compared to the previous year.
முக்கிய அம்சங்கள்
Revenue from operations grew 10.9% YoY to ₹113.92 crore in Q3 FY26.Net profit for the quarter fell 32.3% YoY to ₹4.83 crore from ₹7.13 crore in the previous year.Nine-month (9M FY26) revenue increased to ₹372.06 crore, up from ₹313.72 crore in 9M FY25.Finance costs for the nine-month period rose sharply to ₹8.39 crore from ₹5.28 crore YoY.Appointment of Mr. Ranjit Kumar Kilaru as CFO effective March 01, 2026, following the retirement of the incumbent.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the company is facing margin compression despite revenue growth, likely due to rising operational and finance costs. Monitor how the new CFO manages the debt syndication and financial structuring to improve the bottom line.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
